Thrivent Financial for Lutherans Sells 191,205 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Thrivent Financial for Lutherans lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 33.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 374,659 shares of the medical research company’s stock after selling 191,205 shares during the quarter. Thrivent Financial for Lutherans owned about 0.73% of Charles River Laboratories International worth $77,397,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Czech National Bank boosted its holdings in shares of Charles River Laboratories International by 0.5% during the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock worth $2,445,000 after buying an additional 41 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Charles River Laboratories International by 1.0% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after acquiring an additional 45 shares during the last quarter. Tortoise Investment Management LLC boosted its holdings in Charles River Laboratories International by 77.0% during the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares during the period. Dumont & Blake Investment Advisors LLC grew its position in shares of Charles River Laboratories International by 1.4% in the first quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 62 shares during the last quarter. Finally, Mitchell & Pahl Private Wealth LLC increased its stake in shares of Charles River Laboratories International by 2.0% in the second quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 1.8 %

CRL opened at $205.79 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $161.65 and a 1-year high of $275.00. The stock has a market capitalization of $10.60 billion, a PE ratio of 24.21, a PEG ratio of 3.89 and a beta of 1.36. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $209.34 and a two-hundred day moving average price of $223.80.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its board has approved a share repurchase plan on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 9.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Analyst Ratings Changes

Several analysts recently weighed in on the company. TD Cowen decreased their target price on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. UBS Group reduced their price objective on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Mizuho initiated coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price on the stock. The Goldman Sachs Group reduced their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Finally, Barclays decreased their price target on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 8th. Ten analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $230.93.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).